Resumen
Definición
Anamnesis y examen
Principales factores de diagnóstico
- número de cigarros por dia
- tempo até o primeiro cigarro (TTFC)
- uso de produtos alternativos de administração de tabaco e nicotina
- história de transtorno relacionado ao uso de substâncias
- gestação ou amamentação
Otros factores de diagnóstico
- história de depressão
- história de esquizofrenia
- transtorno convulsivo
- hipertensão
- doença cardíaca instável
- arritmia ventricular
- asma
- doença pulmonar obstrutiva crônica (DPOC)
- distúrbio da articulação temporomandibular ou problema dentário
Factores de riesgo
- idade <24 anos
- condição socioeconômica baixa
- história de transtorno mental ou transtorno por uso de substâncias
- história de HIV/AIDS
- uso de produtos alternativos de administração de tabaco e nicotina
- genética
Pruebas diagnósticas
Primeras pruebas diagnósticas para solicitar
- autorrelato da condição de fumante
- Teste de Fagerström para a dependência de nicotina (Fagerström Test For Nicotine Dependence; FTND)
- Índice de Intensidade do Tabagismo (Heaviness of Smoking Index; HSI)
Pruebas diagnósticas que deben considerarse
- monitoramento do monóxido de carbono (CO)
- nível de cotinina
Algoritmo de tratamiento
fumantes ativos hospitalizados
fumantes ativos prontos para parar: adultos (não gestantes/lactantes)
fumantes ativos dispostos a parar: gestantes/lactantes ou adolescentes
fumantes ativos não dispostos a parar
Colaboradores
Autores
Franck F. Rahaghi, MD, MHS, FCCP
Chairman
Pulmonary Department
Director
Pulmonary Education and Rehabilitation
Cleveland Clinic
Weston
FL
Divulgaciones
FFR is a consultant and speaker for Bayer, United Therapeutics, Janssen-PH, Merck, Boehringer Ingleheim, Takeda, and Talecris. He is involved in industry-sponsored research with Bayer, Janssen-PH, Gossamer Bio, and Bellerophon.
Samuel Gurevich, MD, FCCP
Pulmonary Department
Director
Respiratory Therapy
Cleveland Clinic
Weston
FL
Divulgaciones
SG declares that he has no competing interests.
Agradecimientos
Dr Franck F. Rahaghi and Dr Samuel Gurevich would like to gratefully acknowledge Dr Felix Hernandez, Dr Jose Gonzalez, and Dr Theodore W. Marcy, previous contributors to this topic.
Divulgaciones
FH, JG, and TWM declare that they have no competing interests.
Revisores por pares
Jaymin Morjaria, MBBS, FRCP, MD
Consultant Respiratory Physician
Guy’s and St Thomas NHS Foundation Trust
Harefield Hospital
Middlesex
Honorary Senior Lecturer
Brunel University
London
UK
Divulgaciones
JM has received honoraria for speaking and financial support to attend meetings/advisory boards from Wyeth, Chiesi, Pfizer, MSD, Boehringer Ingelheim, Teva, GSK/Allen & Hanburys, Napp, Almirall, AstraZeneca, Trudell, Cook Medical, Medela AG, Medtronics, and Novartis. He has been an expert witness in a court case relating to the impact of smoking on illness severity, ITU admissions, and mortality from Covid-19 in South Africa in 2020.
Arran Woodhouse, MSc
Senior Tobacco Programme Manager
North Central London Integrated Care Board
London
UK
Divulgaciones
AW has been reimbursed by Johnson & Johnson Ltd Nicorette UK Consulting for chairing the Smoking Cessation National Advisory Panel on 1 November 2022. He worked with NICE on the recent Tobacco Guideline (NG209) as a topic expert and as a specialist committee member for the treating dependence Quality Standards Advisory Committee (QS 207). He was appointed as an Expert Adviser for the NICE Centre for Guidelines in February 2023. Previous member of the British Thoracic Society's Tobacco Specialist Advisory Group.
Agradecimiento de los revisores por pares
Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.
Divulgaciones
Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.
Referencias
Artículos principales
United States Public Health Service Office of the Surgeon General; National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. Smoking cessation: a report of the Surgeon General. 2020 [internet publication].Texto completo Resumen
Tobacco Use and Dependence Guideline Panel, US Department of Health and Human Services. Treating tobacco use and dependence: 2008 update. Rockville (MD): US Department of Health and Human Services; 2008.Texto completo
National Institute for Health and Care Excellence. Tobacco: preventing uptake, promoting quitting and treating dependence. Feb 2025 [internet publication].Texto completo
US Preventive Services Task Force. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA. 2021 Jan 19;325(3):265-79.Texto completo Resumen
Barua RS, Rigotti NA, Benowitz NL, et al. 2018 ACC expert consensus decision pathway on tobacco cessation treatment: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2018 Dec 5;72(25):3332-65.Texto completo Resumen
Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018 May 31;(5):CD000146.Texto completo Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.

Diferenciales
- Transtorno relacionado ao uso de substâncias
Más DiferencialesGuías de práctica clínica
- Tobacco: preventing uptake, promoting quitting and treating dependence
- NCCN clinical practice guidelines in oncology: smoking cessation
Más Guías de práctica clínicaFolletos para el paciente
Abandono do hábito de fumar
Más Folletos para el pacienteInicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad